[1] Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clin Mol Hepatol, 2024, 30(2):135-143. [2] Zhao Q, Liu H, Tang L, et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res,2024, 221:105782. [3] Buti M, Heo J, Tanaka Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol, 2025, 82(2):222-234. [4] Zhang S, Mak LY, Yuen MF, et al. Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B. Clin Mol Hepatol,2025, 31(Suppl):S182-S195. [5] Sapmaz FP, Büyükturan G, Sakin YS, et al. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients? Medicine (Baltimore), 2022, 101(36):e30488. [6] Moosavy SH, Eftekhar E, Davoodian P, et al. AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. BMC Gastroenterol, 2023, 23(1):145. [7] Kang NL, Ruan QF, Zhang DS, et al. Advantages of a novel model for predicting hepatic fibrosis in chronic hepatitis B virus carriers compared with APRI and FIB-4 scores. J Clin Transl Hepatol, 2022, 10(3):412-419. [8] Rojano-Alfonso C, López-Vicario C, Romero-Grimaldo B, et al. Hyaluronic acid in liver fibrosis: Role in inflammation, tissue remodeling, and disease progression. Int J Mol Sci, 2025, 26(20):10139. [9] Rizzo L, L'Abbate L, Attanasio M, et al. Depth effect on point shear wave velocity elastography: Evidence in a chronic hepatitis C patient cohort. Ultrasound, 2024, 32(1):53-61. [10] Wang X, Liu B, Wu C, et al. Shear wave trajectory detection in ultra-fast M-mode images for liver fibrosis assessment: A deep learning-based line detection approach. Ultrasonics, 2024, 142:107358. [11] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020,23 (1):9-32. [12] Liu H, FuY, Guo D, et al. TMM: A comprehensive CAD system for hepatic fibrosis 5-grade METAVIR staging based on liver MRI. Med Phys, 2024, 51(3):2032-2043. [13] Duseja A, Singh SP, De A, et al. Indian National Association for Study of the Liver (INASL) Guidance Paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol, 2023, 13(2):273-302. [14] Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol, 2022, 20(11):2567-2576.e6. [15] 汤洁, 姜正伟, 周冰清, 等. 超声剪切波弹性成像检查联合APRI和FIB-4诊断血清HBeAg阳性慢性乙型肝炎患者肝纤维化程度价值研究. 实用肝脏病杂志, 2025, 28(5):663-666. [16] Shinn J, Park S, Lee S, et al. Antioxidative hyaluronic acid-bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy. ACS Nano, 2024, 18(6):4704-4716. [17] Yu F, Liu Z, Feng J, et al. Hyaluronic acid modified extracellular vesicles targeting hepatic stellate cells to attenuate hepatic fibrosis. Eur JPharm Sci, 2024, 198:106783. [18] Sun M, Zhong M, Luo F, et al. Assessment of liver fibrosis with multisample point shear wave elastography in obese patients with metabolic dysfunction-associated steatotic liver disease. Acad Radiol, 2025, 32(9):5150-5161. [19] Schäfer A, Kovacs MS, Eder A, et al. Longitudinal assessment of liver stiffness using ARFI technique does not support increased risk of fibrosis in rheumatoid arthritis patients on methotrexate. J Ultrasound, 2025, 28(2):323-329. [20] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版).中华肝脏病杂志,2019,27(3):182-191. |